Rhythm Pharmaceuticals Share Price Today
(NASDAQ: RYTM)

Name: Rhythm Pharmaceuticals Share Price Today (NASDAQ: RYTM) - Rhythm Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Rhythm Pharmaceuticals share price is $55.21 & ₹4,765.40 as on 20 Mar 2025, 2.30 'hrs' IST

$55.21

▲

2.92

(5.58%)

Market is closed - opens 7 PM, 20 Mar 2025

View live Rhythm Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Rhythm Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Rhythm Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Rhythm Pharmaceuticals share price movements

Today's Low: $52.20
Today's High: $55.86
$55.21
5.45%
Downside
Day's Volatility :6.54%
Upside
1.15%
52 Weeks Low: $35.17
52 Weeks High: $68.58
$55.21
36.3%
Downside
52 Weeks Volatility :48.72%
Upside
19.5%

Rhythm Pharmaceuticals (RYTM) Returns

Period	Rhythm Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-5.75%	7.7%	0.0%
6 Months	-4.14%	-5.8%	0.0%
1 Year	31.78%	0.7%	0.0%
3 Years	364.8%	7.2%	-15.2%

Rhythm Pharmaceuticals (RYTM) Key Statistics

in dollars & INR

Previous Close	$52.29
Open	$52.25
Today's High	$55.855
Today's Low	$52.2
Market Capitalization	$3.3B
Today's Volume	$391.9K
52 Week High	$68.58
52 Week Low	$35.17
Revenue TTM	$130.1M
EBITDA	$-263.9M
Earnings Per Share (EPS)	$-4.34
Profit Margin	-200.27%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-155.91%

How to invest in Rhythm Pharmaceuticals Stock (RYTM) from India?

It is very easy for Indian residents to invest directly in Rhythm Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Rhythm Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Rhythm Pharmaceuticals or RYTM on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Rhythm Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Rhythm Pharmaceuticals shares which would translate to 0.016 fractional shares of Rhythm Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Rhythm Pharmaceuticals, in just a few clicks!

Returns in Rhythm Pharmaceuticals (RYTM) for Indian investors in Rupees

The Rhythm Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Rhythm Pharmaceuticals investment value today

Current value as on today

₹1,43,156

Returns

₹43,156

(+43.16%)

Returns from Rhythm Pharmaceuticals Stock

₹39,138 (+39.14%)

Dollar Returns

₹4,018 (+4.02%)

Indian investors sentiment towards Rhythm Pharmaceuticals (RYTM)

-31%

Period: Feb 17, 2025 to Mar 19, 2025. Change in 30 Days versus previous period

Search interest for Rhythm Pharmaceuticals Stock from India on INDmoney has decreased by -31% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Rhythm Pharmaceuticals

BlackRock Inc
10.99%
PRIMECAP Management Company
10.39%
RA Capital Management, LLC
9.62%
Baker Bros Advisors LP
9.62%
Perceptive Advisors LLC
5.82%
Vanguard Group Inc
5.45%

Analyst Recommendation on Rhythm Pharmaceuticals

Buy

93%Buy

6%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Rhythm Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Rhythm Pharmaceuticals Stock (RYTM)

What analysts predicted

Upside of 36.0%

Target:

$75.08

Current:

$55.21

Insights on Rhythm Pharmaceuticals Stock (Ticker Symbol: RYTM)

Price Movement
In the last 3 years, RYTM stock has moved up by 364.8%
Increasing Revenue
Revenue is up for the last 10 quarters, 4.28M → 41.83M (in $), with an average increase of 20.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -44.97M → -43.29M (in $), with an average increase of 3.9% per quarter
RYTM vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 64.9% return, outperforming this stock by 31.2%
Price to Sales
ForRYTM every $1 of sales, investors are willing to pay $25.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.4 for every $1 of sales.

Rhythm Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Rhythm Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Rhythm Pharmaceuticals (RYTM) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Rhythm Pharmaceuticals Inc	-9.14%	-4.14%	31.78%	364.8%	167.74%
Regeneron Pharmaceuticals, Inc.	-2.21%	-42.19%	-31.23%	-4.07%	45.94%
Beone Medicines Ltd	9.77%	31.62%	54.1%	45.52%	104.52%
Vertex Pharmaceuticals Incorporated	10.85%	7.18%	24.29%	104.68%	153.32%
Alnylam Pharmaceuticals, Inc.	-2.28%	-11.59%	65.08%	50.4%	146.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Rhythm Pharmaceuticals Inc	NA	NA	NA	-2.44	-1.56	-0.46	NA	0.35
Regeneron Pharmaceuticals, Inc.	17.7	17.7	1.0	42.64	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.45	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.43	18.06	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.52	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Rhythm Pharmaceuticals Inc	Buy	$3.3B	167.74%	NA	-200.27%
Regeneron Pharmaceuticals, Inc.	Buy	$74.2B	45.94%	17.7	31.07%
Beone Medicines Ltd	NA	$28.4B	104.52%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$131.9B	153.32%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$32.8B	146.62%	NA	-12.37%

Rhythm Pharmaceuticals Dividend announcements

Rhythm Pharmaceuticals Earnings
Rhythm Pharmaceuticals’s price-to-earnings ratio stands at None

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

Organization	Rhythm Pharmaceuticals
Employees	283
CEO	Dr. David P. Meeker M.D.
Industry	Health Technology

Management People of Rhythm Pharmaceuticals

Name	Title
Dr. David P. Meeker M.D.	Chairman, President & CEO
Mr. Hunter C. Smith M.B.A.	CFO & Treasurer
Mr. Joseph Shulman	Chief Technical Officer
Mr. Yann Mazabraud	Executive VP & Head of International
Ms. Jennifer Lee	Executive VP & Head of North America
Mr. Christopher P. German	Corporate Controller & Principal Accounting Officer
Dr. Alastair Garfield Ph.D.	Chief Scientific Officer
Mr. David Connolly	Head of Investor Relations & Corporate Communications
Mr. Jim Flaherty	Senior VP & General Counsel
Ms. Sarah Ryan	Vice President of Sales & Marketing

Important FAQs about investing in RYTM Stock from India :

What is Rhythm Pharmaceuticals share price today?

Rhythm Pharmaceuticals share price today stands at $55.21, Open: $52.25 ; Previous Close: $52.29 ; High: $55.86 ; Low: $52.20 ; 52 Week High: $68.58 ; 52 Week Low: $35.17.

The stock opens at $52.25, after a previous close of $52.29. The stock reached a daily high of $55.86 and a low of $52.20, with a 52-week high of $68.58 and a 52-week low of $35.17.

Can Indians buy Rhythm Pharmaceuticals shares?

Yes, Indians can invest in the Rhythm Pharmaceuticals (RYTM) from India.

With INDmoney, you can buy Rhythm Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Rhythm Pharmaceuticals at zero transaction cost.

How can I buy Rhythm Pharmaceuticals shares from India?

It is very easy to buy Rhythm Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Rhythm Pharmaceuticals (RYTM) be purchased?

Yes, you can buy fractional shares of Rhythm Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Rhythm Pharmaceuticals stocks?

To start investing in Rhythm Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.